[1] |
LUKE J J,FLAHERTY K T,RIBAS A,et al. Targeted agents and immunotherapies:optimizing outcomes in melanoma[J]. Nat Rev Clin Oncol,2017,14(8):463-482.
|
[2] |
BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
[3] |
CHI Z,LI S,SHENG X,et al. Clinical presentation,histology,and prognoses of malignant melanoma in ethnic Chinese:a study of 522 consecutive cases[J]. BMC Cancer,2011,11:85.
|
[4] |
ALIX-PANABIÈRES C,SCHWARZENBACH H,PANTEL K. Circulating tumor cells and circulating tumor DNA[J]. Annu Rev Med,2012,63:199-215.
|
[5] |
PINZANI P,SALVIANTI F,CASCELLA R,et al. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients[J]. Clin Chim Acta,2010,411(17-18):1319-1324.
|
[6] |
TANG H,KONG Y,SI L,et al. Clinical significance of BRAFV600E mutation in circulating tumor DNA in Chinese patients with melanoma[J]. Oncol Lett,2018,15(2):1839-1844.
|
[7] |
HASELMANN V,GEBHARDT C,BRECHTEL I,et al. Liquid profiling of circulating tumor DNA in plasma of melanoma patients for companion diagnostics and monitoring of BRAF inhibitor therapy[J]. Clin Chem,2018,64(5):830-842.
|
[8] |
邬兰,张永,曾宪涛. QUADAS-2在诊断准确性研究的质量评价工具中的应用[J]. 湖北医药学院学报,2013,32(3):201-208.
|
[9] |
MOSKO M J,NAKORCHEVSKY A A,FLORES E,et al. Ultrasensitive detection of multiplexed somatic mutations using MALDI-TOF mass spectrometry[J]. J Mol Diagn,2016,18(1):23-31.
|
[10] |
SANTIAGO-WALKER A,GAGNON R,MAZUMDAR J,et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials[J]. Clin Cancer Res,2016,22(3):567-574.
|
[11] |
LONG-MIRA E,ILIE M,CHAMOREY E,et al. Monitoring BRAF and NRAS mutations with cell-free circulating tumor DNA from metastatic melanoma patients[J]. Oncotarget,2018,9(90):36238-36249.
|
[12] |
JANKU F,HUANG H J,CLAES B,et al. BRAF mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid,automated molecular diagnostics system[J]. Mol Cancer Ther,2016,15(6):1397-1404.
|
[13] |
BOARD R E,ELLISON G,ORR M C M,et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244(ARRY-142886) advanced melanoma phase Ⅱ study[J]. Br J Cancer,2009,101(10):1724-1730.
|
[14] |
AUNG K L,DONALD E,ELLISON G,et al. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system[J]. J Mol Diagn,2014,16(3):343-349.
|
[15] |
ROWE S P,LUBER B,MAKELL M,et al. From validity to clinical utility:the influence of circulating tumor DNA on melanoma patient management in a real-world setting[J]. Mol Oncol,2018,12(10):1661-1672.
|
[16] |
YANCVITZ M,YOON J,MIKHAIL M,et al. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma[J]. J Mol Diagn,2007,9(2):178-183.
|
[17] |
梁维君. 医药统计学[M]. 7版. 北京:中国医药科技出版社,2006.
|
[18] |
YANG Y C,WANG D,JIN L,et al. Circulating tumor DNA detectable in early- and late-stage colorectal cancer patients[J]. Biosci Rep,2018,38(4):BSR20180322.
|
[19] |
LIM S H,BECKER T M,CHUA W,et al. Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer[J]. Cancer Lett,2014,346(1):24-33.
|
[20] |
刘毅,张少华,吴一龙,等. 中国临床肿瘤学进展 [M]. 北京:人民卫生出版社,2017.
|
[21] |
WAN J C M,MASSIE C,GARCIA-COBACHO J,et al. Liquid biopsies come of age:towards implementation of circulating tumour DNA[J]. Nat Rev Cancer,2017,17(4):223-238.
|
[22] |
SIRAVEGNA G,MARSONI S,SIENA S,et al. Integrating liquid biopsies into the management of cancer[J]. Nat Rev Clin Oncol,2017,14(9):531-548.
|
[23] |
李慧敏,马清光,李洪英. 胸腔积液γ-干扰素释放试验对结核性胸腔积液诊断价值的Meta分析[J]. 检验医学,2018,33(2):139-146.
|